Sugi Predict

Sugi Predict / Compounds / SCHEMBL4954775

SCHEMBL4954775

SCHEMBL4954775

Cn1c2ccc(F)cc2c2c(C(=O)N3CCCC3)cn(-c3ccccc3)c(=O)c21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 9/20 0.53
▸ ALDH1A1 P00352 9/20 0.53
▸ HSD17B10 Q99714 8/20 0.53
▸ KDM4E B2RXH2 8/20 0.53
▸ SMN1; SMN2 Q16637 4/20 0.53
▸ NPSR1 Q6W5P4 2/20 0.53
▸ LMNA P02545 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ MAPT P10636 2/20 0.51
▸ TP53 P04637 1/20 0.51
▸ TSHR P16473 1/20 0.46
▸ GAA P10253 6/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ ALOX15 P16050 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ GLA P06280 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7408771 0.86 KDM4E (0.52) HPGDALDH1A1HSD17B10KDM4ESMN1; SMN2
SCHEMBL7412441 0.82 SRC (0.44) ALDH1A1KDM4ESMN1; SMN2LMNAMAPT
SCHEMBL7413021 0.82 KDM4E (0.45) HPGDALDH1A1HSD17B10KDM4ESMN1; SMN2
SCHEMBL7413480 0.82 ALDH1A1 (0.44) HPGDALDH1A1HSD17B10KDM4ESMN1; SMN2
SCHEMBL7407974 0.80 KDM4E (0.41) HPGDALDH1A1HSD17B10KDM4ESMN1; SMN2
SCHEMBL7411367 0.80 KDM4E (0.44) HPGDALDH1A1HSD17B10KDM4ELMNA
SCHEMBL7411565 0.73 KDM4E (0.48) HPGDALDH1A1HSD17B10KDM4ESMN1; SMN2
SCHEMBL4753357 0.69 MAPT (0.81) HPGDALDH1A1HSD17B10KDM4ESMN1; SMN2
SCHEMBL7412091 0.69 GAA (0.49) HPGDALDH1A1HSD17B10KDM4ESMN1; SMN2
SCHEMBL7415364 0.69 KDM4E (0.46) HPGDALDH1A1HSD17B10KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025024501-A1 NEUROMODULATORY PEPTIDES LACTOCORE, INC. (US) 2025-01-30 — — WO claimed
US-20240390311-A1 COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-11-28 — — US claimed
EP-4405049-A1 COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS The Regents of the University of California (US) 2024-07-31 — — EP claimed
US-20230381125-A1 COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-11-30 — — US claimed
EP-4217002-A1 COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS The Regents of the University of California (US) 2023-08-02 — — EP claimed
WO-2023101899-A1 COMPOSITIONS AND METHODS FOR AMELIORATING SJOGREN'S SYNDROME THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-08 — — WO claimed
WO-2023048781-A1 COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS RELATING TO CORONAVIRUS INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-03-30 — — WO claimed
US-20220117916-A1 Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose SAFERX PHARMACEUTICALS LLC (US) 2022-04-21 — — US claimed
WO-2022067044-A1 COMPOSITIONS AND METHODS FOR AMELIORATING MEDICAL CONDITIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-03-31 — — WO claimed
EP-1895982-A2 STABLE NANOPARTICLE FORMULATIONS Sanofi-Aventis U.S. LLC (US) 2008-03-12 — — EP claimed
US-20080038359-A1 Stable Nanoparticle Formulations SANOFI-AVENTIS U.S. LLC (US) 2008-02-14 — — US claimed
WO-2007086911-A2 STABLE NANOPARTICLE FORMULATIONS SANOFI-AVENTIS U.S. LLC (US) 2007-08-02 — — WO claimed
WO-2006061428-A2 GABA-A ALPHA 2 AND ALPHA 3 RECEPTOR AGONISTS FOR TREATING NEUROPATHIC, INFLAMMATORY AND MIGRAINE ASSOCIATED PAIN Universität Zürich (CH) 2006-06-15 — — WO claimed
US-20250163130-A1 LIGAND GATED ION CHANNELS AND METHODS OF USE SWITCH BIO, INC. 2025-05-22 — — US disclosed
US-20250152742-A1 COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES TRAMES BIO, INC. 2025-05-15 — — US disclosed
WO-2025024501-A1 NEUROMODULATORY PEPTIDES LACTOCORE, INC. (US) 2025-01-30 — — WO disclosed
US-20080038359-A1 Stable Nanoparticle Formulations SANOFI-AVENTIS U.S. LLC (US) 2008-02-14 — — US disclosed
WO-2007086911-A2 STABLE NANOPARTICLE FORMULATIONS SANOFI-AVENTIS U.S. LLC (US) 2007-08-02 — — WO disclosed
EP-0934319-B1 1H-PYRIDO[3,4-b]INDOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS SANOFI SYNTHELABO (FR) 2002-06-05 — — EP disclosed
US-6075021-A 1H-pyrido[3,4-b]indole-4-carboxamide derivatives, preparation and application thereof in therapeutics SYNTHELABO (FR) 2000-06-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080038359-A1 Stable Nanoparticle Formulations NPC1L1, NPC1, CD63 HPGD 746/4885ALDH1A1 394/4885HSD17B10 2858/4885
US-20250152742-A1 COMPOSITIONS AND METHODS FOR NEUROLOGICAL DISEASES CHRNB2, CHRNA2, CHRNA6 HPGD 4092/4885ALDH1A1 4527/4885HSD17B10 4285/4885
US-20250163130-A1 LIGAND GATED ION CHANNELS AND METHODS OF USE CACNB2, CHRNA2, HCN3 HPGD 3633/4885ALDH1A1 4062/4885HSD17B10 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.